Publicacións en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (10)

2022

  1. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 2

2021

  1. Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study

    European Journal of Cancer, Vol. 151, pp. 49-62

  2. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  3. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2014

  1. Predicting response and survival in chemotherapy-treated triple-negative breast cancer

    British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541

2013

  1. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer

    Breast Cancer Research and Treatment, Vol. 138, Núm. 2, pp. 457-466

2012

  1. Ixabepilone-associated peripheral neuropathy: Data from across the phase II and III clinical trials

    Supportive Care in Cancer, Vol. 20, Núm. 11, pp. 2661-2668

2011

  1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784

2010

  1. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

    Journal of the National Cancer Institute - Monographs, Vol. 41, pp. 162-177

2005

  1. The global breast cancer burden: Variations in epidemiology and survival

    Clinical Breast Cancer, Vol. 6, Núm. 5, pp. 391-401